+265.1%
MU vs MRNA
+945.0%
-679.9%
-39.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -7.0% | +13.1% | -20.1% | -7.4% |
| 7D | -19.1% | +20.6% | -39.8% | -19.6% |
| 30D | -25.2% | +27.1% | -52.4% | -25.8% |
| 3M | -10.9% | +353.4% | -364.3% | -18.9% |
| 6M | +38.0% | +446.3% | -408.3% | +14.5% |
| YTD | +178.8% | +776.2% | -597.3% | +92.1% |
| 1Y | +265.1% | +987.9% | -722.8% | +132.5% |
| All | +265.1% | +945.0% | -679.9% | +132.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling